We have previously reported that the intralesional administration of two immunocytokine products (L19-IL2 and L19-TNF) was able to induce cancer remission both in mouse models of cancer (24) and in patients with stage IIIB/C melanoma (22). This evidence concerns the gene IL2 and melanoma.